从医疗保健系统角度看实施基因组医学：以儿科急性淋巴细胞白血病为例。
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm.
机构信息
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2013 Aug;94(2):224-9. doi: 10.1038/clpt.2013.9. Epub 2013 Jan 17.
Abstract
The promise of genomic medicine has received great attention over the past decade, projecting how genomics will soon guide the prevention, diagnosis, and treatment of human diseases. However, this evolution has been slower than forecast, even where evidence is often strong (e.g., pharmacogenomics). Reasons include the requirement for institutional resources and the need for the will to push beyond barriers impeding health-care changes. Here, we illustrate how genomics has been deployed to advance the treatment of childhood leukemia.
摘要
过去十年中，基因组医学的前景引起了广泛关注，人们预测基因组学将很快指导人类疾病的预防、诊断和治疗。然而，即使在证据通常很充分的情况下（例如，药物基因组学），这一演变速度也比预期的要慢。原因包括对机构资源的需求以及克服阻碍医疗保健变革的障碍的意愿。在这里，我们举例说明了如何利用基因组学来推进儿童白血病的治疗。
相似文献
1
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm.从医疗保健系统角度看实施基因组医学：以儿科急性淋巴细胞白血病为例。
Clin Pharmacol Ther. 2013 Aug;94(2):224-9. doi: 10.1038/clpt.2013.9. Epub 2013 Jan 17.
2
Clonotypic analysis of acute lymphoblastic leukemia with a double TEL-AML1 fusion at onset and relapse.初发及复发时具有双 TEL-AML1 融合的急性淋巴细胞白血病的克隆型分析。
Leukemia. 2006 Feb;20(2):363-5. doi: 10.1038/sj.leu.2404077.
3
Pediatric acute lymphoblastic leukemia: there is no TEL-ing what wonders lie ahead.小儿急性淋巴细胞白血病：未来的奇迹难以限量。 （注：TEL在医学领域可能有特定含义，这里结合语境意译，整体句子利用了双关，既包含字面意思，又暗示TEL相关与白血病治疗奇迹的关联 ）
Leuk Res. 2010 Apr;34(4):418-9. doi: 10.1016/j.leukres.2009.10.009. Epub 2009 Nov 4.
4
Expression of Tel-Aml1 transcript variants in pediatric acute lymphoblastic leukemia.Tel-Aml1转录变体在儿童急性淋巴细胞白血病中的表达
Leukemia. 2006 Jan;20(1):165-7. doi: 10.1038/sj.leu.2404028.
5
High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.作为 ETV6-RUNX1 阳性急性淋巴细胞白血病反应监测的单一标志物，基因组融合具有高灵敏度和克隆稳定性。
Pediatr Blood Cancer. 2019 Aug;66(8):e27780. doi: 10.1002/pbc.27780. Epub 2019 Apr 29.
6
A novel TEL-AML1 fusion transcript involving the pro-apoptotic gene BCL-G in pediatric precursor B acute lymphoblastic leukemia.一种涉及促凋亡基因BCL-G的新型TEL-AML1融合转录本在儿童前体B淋巴细胞白血病中的研究
Leukemia. 2006 Jul;20(7):1294. doi: 10.1038/sj.leu.2404249. Epub 2006 May 4.
7
Chimeric fusion karyotypes in childhood B-cell acute lymphoblastic leukemia.儿童B细胞急性淋巴细胞白血病中的嵌合融合核型
Indian Pediatr. 2014 Feb;51(2):152-3.
8
Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia.多重复发急性淋巴细胞白血病综合临床测序揭示的隐匿性ETV6-ABL1融合和MLL2截短
J Pediatr Hematol Oncol. 2019 Nov;41(8):653-656. doi: 10.1097/MPH.0000000000001249.
9
Insights into the prenatal origin of childhood acute lymphoblastic leukemia.儿童急性淋巴细胞白血病的产前起源研究进展。
Cancer Metastasis Rev. 2020 Mar;39(1):161-171. doi: 10.1007/s10555-019-09841-1.
10
[Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia].124例儿童急性淋巴细胞白血病患者的经典及分子细胞遗传学异常
Zhonghua Er Ke Za Zhi. 2007 Sep;45(9):684-6.
引用本文的文献
1
Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia.实施药物遗传学以个体化急性淋巴细胞白血病患儿的治疗方案。
Pharmgenomics Pers Med. 2020 Aug 12;13:295-317. doi: 10.2147/PGPM.S239602. eCollection 2020.
2
Evidence and resources to implement pharmacogenetic knowledge for precision medicine.实施精准医学药物遗传学知识的证据和资源。
Am J Health Syst Pharm. 2016 Dec 1;73(23):1977-1985. doi: 10.2146/ajhp150977.
3
Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.1988 - 2011年加利福尼亚州急性髓系白血病儿童、青少年及年轻成人早期死亡和生存的预测因素：一项基于人群的研究
Br J Haematol. 2016 Apr;173(2):292-302. doi: 10.1111/bjh.13944. Epub 2016 Feb 5.
4
Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents.需考虑的要点：儿童和青少年基因检测的伦理、法律及社会心理影响
Am J Hum Genet. 2015 Jul 2;97(1):6-21. doi: 10.1016/j.ajhg.2015.05.022.
5
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.PG4KDS：一种用于抢先式药物遗传学临床应用的模型。
Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):45-55. doi: 10.1002/ajmg.c.31391. Epub 2014 Mar 11.
6
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.亚洲成人和儿科急性淋巴细胞白血病的管理：2013 年亚洲肿瘤峰会的资源分层指南。
Lancet Oncol. 2013 Nov;14(12):e508-23. doi: 10.1016/S1470-2045(13)70452-2.
7
Development and use of active clinical decision support for preemptive pharmacogenomics.主动临床决策支持在预测性药物基因组学中的开发和应用。
J Am Med Inform Assoc. 2014 Feb;21(e1):e93-9. doi: 10.1136/amiajnl-2013-001993. Epub 2013 Aug 26.
8
A 50-year journey to cure childhood acute lymphoblastic leukemia.治愈儿童急性淋巴细胞白血病的 50 年历程。
Semin Hematol. 2013 Jul;50(3):185-96. doi: 10.1053/j.seminhematol.2013.06.007.
9
Genomic medicine, precision medicine, personalized medicine: what's in a name?基因组医学、精准医学、个性化医学：名称背后的含义是什么？
Clin Pharmacol Ther. 2013 Aug;94(2):169-72. doi: 10.1038/clpt.2013.101.
本文引用的文献
1
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.诱导后地塞米松和大肠杆菌 L-天冬酰胺酶的个体化剂量均可改善新诊断的儿童和青少年急性淋巴细胞白血病的预后：来自 Dana-Farber 癌症研究所 ALL 联盟方案 00-01 的一项随机研究结果。
J Clin Oncol. 2013 Mar 20;31(9):1202-10. doi: 10.1200/JCO.2012.43.2070. Epub 2013 Jan 28.
2
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record.一种由临床医生驱动的自动化系统，用于将药物遗传学解释整合到电子病历中。
Clin Pharmacol Ther. 2012 Nov;92(5):563-6. doi: 10.1038/clpt.2012.140. Epub 2012 Sep 19.
3
Pharmacogenomics and individualized medicine: translating science into practice.药物基因组学与个体化医学：将科学转化为实践。
Clin Pharmacol Ther. 2012 Oct;92(4):467-75. doi: 10.1038/clpt.2012.120. Epub 2012 Sep 5.
4
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.高危急性淋巴细胞白血病中激活激酶和细胞因子受体信号的遗传改变。
Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.
5
The Pediatric Cancer Genome Project.儿科癌症基因组计划。
Nat Genet. 2012 May 29;44(6):619-22. doi: 10.1038/ng.2287.
6
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.前瞻性个体化医疗基因分型的实施：范德堡 PREDICT 项目的设计。
Clin Pharmacol Ther. 2012 Jul;92(1):87-95. doi: 10.1038/clpt.2011.371. Epub 2012 May 16.
7
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.1990 至 2005 年期间儿童及青少年急性淋巴细胞白血病存活率的提高：儿童肿瘤协作组的报告。
J Clin Oncol. 2012 May 10;30(14):1663-9. doi: 10.1200/JCO.2011.37.8018. Epub 2012 Mar 12.
8
Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.美国医生采用药物基因组学检测的情况：全国性调查结果。
Clin Pharmacol Ther. 2012 Mar;91(3):450-8. doi: 10.1038/clpt.2011.306. Epub 2012 Jan 25.
9
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.早期 T 细胞前体急性淋巴细胞白血病的遗传基础。
Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.
10
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.临床药物遗传学实施联盟（CPIC）关于细胞色素 P450 2D6（CYP2D6）基因型背景下的可待因治疗指南。
Clin Pharmacol Ther. 2012 Feb;91(2):321-6. doi: 10.1038/clpt.2011.287. Epub 2011 Dec 28.
Zotero 插件